Details for New Drug Application (NDA): 020727
✉ Email this page to a colleague
The generic ingredient in BIDIL is hydralazine hydrochloride; isosorbide dinitrate. There are twenty-one drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the hydralazine hydrochloride; isosorbide dinitrate profile page.
Summary for 020727
Tradename: | BIDIL |
Applicant: | Azurity |
Ingredient: | hydralazine hydrochloride; isosorbide dinitrate |
Patents: | 0 |
Pharmacology for NDA: 020727
Physiological Effect | Arteriolar Vasodilation Vasodilation |
Suppliers and Packaging for NDA: 020727
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
BIDIL | hydralazine hydrochloride; isosorbide dinitrate | TABLET;ORAL | 020727 | NDA | Azurity | 24338-010 | 24338-010-09 | 90 TABLET, FILM COATED in 1 BOTTLE (24338-010-09) |
BIDIL | hydralazine hydrochloride; isosorbide dinitrate | TABLET;ORAL | 020727 | NDA AUTHORIZED GENERIC | Wilshire Pharmaceuticals | 52536-006 | 52536-006-09 | 90 TABLET, FILM COATED in 1 BOTTLE (52536-006-09) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 37.5MG;20MG | ||||
Approval Date: | Jun 23, 2005 | TE: | AB | RLD: | Yes |
Expired US Patents for NDA 020727
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Azurity | BIDIL | hydralazine hydrochloride; isosorbide dinitrate | TABLET;ORAL | 020727-001 | Jun 23, 2005 | ⤷ Sign Up | ⤷ Sign Up |
Azurity | BIDIL | hydralazine hydrochloride; isosorbide dinitrate | TABLET;ORAL | 020727-001 | Jun 23, 2005 | ⤷ Sign Up | ⤷ Sign Up |
Azurity | BIDIL | hydralazine hydrochloride; isosorbide dinitrate | TABLET;ORAL | 020727-001 | Jun 23, 2005 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription